Ipamorelin · Research brief

Peptide Purity Levels — Research Quality Standards

Q: How is peptide purity measured and what does the percentage actually represent?

Peptide purity is measured using reverse-phase high-performance liquid chromatography (RP-HPLC), which separates molecules by hydrophobicity and size. The purity percentage represents the proportion of correctly sequenced, full-length target peptide relative to the total peptide content, calculated by dividing the area under the target peak by the total area of all detected peaks on the chromatogram. A 98% pure peptide means 98% of the dry peptide mass (excluding water and salts) is the intended amino acid sequence, with the remaining 2% consisting of deletion sequences, truncated chains, and synthesis by-products. Mass spectrometry complements HPLC by confirming molecular weight within ±0.5 Da, catching gross synthesis errors that HPLC retention time alone might miss.

Q: Can I use a 95% pure peptide for receptor binding assays or do I need 98% purity?

For receptor binding assays, dose-response studies, and any research intended for publication, 98% purity is the minimum reliable threshold. The 3–5% impurity fraction in 95% pure peptides typically consists of deletion sequences and truncated analogs that can bind to the same receptors as the target peptide but without full activation—functioning as competitive antagonists that shift EC50 values and prevent dose-response curves from plateating cleanly. This interference makes data irreproducible across experiments. The cost difference between 95% and 98% purity is 15–25%, but the experimental risk of using lower-purity peptides in mechanistic research consistently outweighs the savings when results don’t replicate.

Q: What types of impurities are included in the remaining percentage of a peptide labeled 98% pure?

The remaining 2% in a 98% pure peptide consists primarily of deletion peptides (sequences missing one or more amino acids at the N- or C-terminus), truncated chains from incomplete synthesis cycles, substitution analogs where the wrong amino acid was inserted during coupling, and incomplete deprotection products where side-chain protecting groups weren’t fully removed. At 98% purity, most deletion peptides have been eliminated through additional RP-HPLC purification passes, leaving trace amounts of enantiomeric impurities (D-amino acids instead of L-amino acids), positional isomers, and residual synthesis reagents. These remaining impurities at the 2% level generally lack significant receptor affinity and don’t interfere with pharmacological mechanism, which is why 98% is the research-grade standard for reproducible binding studies.

Q: How do I verify that a peptide supplier’s advertised purity matches the actual product?

Request a batch-specific certificate of analysis (COA) that includes the batch number, synthesis date, HPLC chromatogram with labeled target peak, mass spectrometry data, and the name and contact information of the third-party testing laboratory. The HPLC chromatogram should show the target peptide as the dominant peak with area integration percentages listed—calculate the purity yourself by dividing the target peak area by total peak area to verify it matches the advertised specification. Legitimate research-grade suppliers provide COAs from accredited independent labs, not in-house testing reported by the same entity that synthesized the peptide. If a supplier cannot provide third-party verification with batch-specific analytical data, assume the purity is lower than advertised and source from a provider with documented quality control like Real Peptides.

Q: Does peptide purity affect stability during storage and how long can I store reconstituted peptides?

Peptide purity primarily affects immediate experimental reproducibility rather than storage stability—the impurities present at synthesis (deletion peptides, truncations) remain constant during storage unless degradation occurs. However, trace impurities can seed aggregation or oxidation during long-term storage, particularly in reconstituted solutions where water accelerates chemical degradation. Lyophilized peptides stored at −20°C maintain purity for 12–24 months regardless of whether they’re 95% or 98% pure at synthesis. Once reconstituted with bacteriostatic water, peptides should be stored at 2–8°C and used within 28 days—purity will decline due to oxidation, aggregation, and hydrolysis, with higher-purity starting material degrading at roughly the same rate as lower-purity peptides once in solution.

Q: What is the difference between HPLC purity and peptide content by weight?

HPLC purity measures the percentage of correctly sequenced target peptide relative to total peptide content, excluding water, salts, and counterions. Peptide content by weight measures the actual mass of all peptide material (target plus impurities) relative to total vial weight, including water and salts. A vial labeled as 10mg of 98% pure peptide with 4% water and 1% acetate counterion contains approximately 9.5mg of dry peptide, of which 98% (9.31mg) is the target sequence. Dosing calculations that ignore water content and assume the entire 10mg is active peptide systematically overdose by 3–7%. Certificates of analysis list both HPLC purity and peptide content—multiply them to determine net active peptide mass per vial.

Q: Why do some peptides cost significantly more even when purity percentages appear similar?

Price differences reflect synthesis difficulty, sequence length, amino acid rarity, and purification complexity beyond the final purity percentage. Peptides with multiple disulfide bonds like Thymosin Alpha 1 require additional oxidation and folding steps that increase synthesis time and reduce yield. Long sequences (>20 amino acids) accumulate deletion errors at each coupling step, requiring multiple purification passes to reach 98% purity. Peptides containing non-standard amino acids—D-amino acids, methylated residues, or beta-amino acids—require custom synthesis protocols and specialized protecting groups that cost 3–5× standard amino acids. Additionally, peptides with hydrophobic sequences aggregate during purification, reducing recovery yield and increasing cost per milligram of final product. A 98% pure 15-amino acid peptide with standard residues costs significantly less than a 98% pure 30-amino acid sequence with two disulfide bonds, even though both meet the same purity specification.

Real Peptides Research TeamEditorial

Updated April 3, 202611 min read

60 WORDS

Short answer

Key takeaways

Peptide purity levels represent the percentage of correctly sequenced full-length peptide measured by HPLC, with impurities including deletion sequences, truncated chains, and synthesis by-products that can interfere with receptor binding.
The jump from 95% to 98% purity eliminates the majority of deletion peptides and truncated sequences that function as competitive antagonists in binding assays, making 98% the minimum threshold for reproducible pharmacological research.
HPLC purity percentages do not account for water content or counterions—a 10mg vial of 98% pure peptide with 4% moisture contains approximately 9.41mg of the target sequence, requiring dose adjustments based on net peptide content.
Mass spectrometry confirms molecular weight within ±0.5 Da but cannot detect positional isomers where amino acids appear in the wrong sequence order—HPLC retention time shifts catch these errors even when molecular weight matches.
For receptor binding studies and dose-response curves using peptides like BPC-157, Ipamorelin, or Thymosin Alpha 1, peptides below 98% purity produce data that doesn't replicate across experiments due to impurity interference with mechanism.
Third-party certificates of analysis with batch-specific HPLC chromatograms and mass spectrometry data are the only reliable verification that peptide purity levels meet research-grade standards—supplier claims without COA documentation cannot be validated.

A peptide marked 95% pure doesn't mean what most researchers think it means. That percentage represents the proportion of the intended full-length amino acid sequence detected by HPLC (high-performance liquid chromatography)—the remaining 5% isn't just "impurity traces." It includes truncated sequences, deletion peptides, and substitution errors that can bind to the same receptors as your target compound but produce opposite or null effects. For compounds like BPC-157 or Thymosin Alpha 1, where the mechanism depends on precise sequence fidelity, that 5% matters more than the price difference between purity grades.

We've reviewed synthesis reports across hundreds of research peptides. The gap between 95% and 98% purity isn't cosmetic—it's the difference between reproducible results and data you can't publish.

What are peptide purity levels and why do they matter for research?

Peptide purity levels quantify the percentage of correctly sequenced, full-length target peptide in a sample, measured through HPLC analysis against known standards. Research-grade peptides typically range from 95% to 99% purity, with each percentage point representing fewer synthesis errors, truncations, and side-chain modifications. Higher purity translates directly to reproducibility—the same dose produces the same receptor occupancy across experiments without interference from deletion sequences or misfolded analogs.

Most published peptide research requires minimum 98% purity for receptor binding studies, but that standard isn't arbitrary. Peptides like Sermorelin and Ipamorelin act on growth hormone secretagogue receptors with nanomolar affinity—truncated sequences missing even one amino acid at the binding terminus can occupy receptors without activating them, functioning as competitive antagonists rather than agonists. A sample with 95% purity and 5% deletion peptides doesn't deliver 95% of the intended effect—it delivers unpredictable results because the impurities actively interfere with the mechanism.

This article covers the analytical methods that define peptide purity levels, the functional differences between purity grades, how synthesis impurities affect experimental outcomes, and the third-party verification practices that separate research-grade suppliers from bulk commodity manufacturers. You'll understand exactly what the purity percentage on a certificate of analysis represents and why it's the single most important specification on any peptide datasheet.

How Peptide Purity Levels Are Measured and What HPLC Analysis Actually Detects

HPLC (high-performance liquid chromatography) is the universal standard for measuring peptide purity levels because it separates molecules by hydrophobicity and size, producing a chromatogram where each peak represents a distinct molecular species. The target peptide appears as the dominant peak—purity percentage is calculated by dividing the area under the target peak by the total area of all peaks detected. A 98% pure peptide means the target sequence accounts for 98% of the total peptide content by mass, with the remaining 2% distributed across deletion sequences, truncated chains, and synthesis by-products.

Two HPLC methods dominate peptide analysis: reverse-phase HPLC (RP-HPLC) and analytical HPLC. RP-HPLC uses a hydrophobic stationary phase and a polar mobile phase—peptides elute based on hydrophobicity, with longer or more hydrophobic sequences retained longer. This method detects deletion peptides (sequences missing one or more amino acids) and substitution errors where a similar amino acid replaced the intended residue. Analytical HPLC operates under the same principle but with higher resolution columns and gradient optimization for specific peptide classes. Both methods require calibration against reference standards—without a known-pure sample for comparison, the chromatogram shows relative abundance but not absolute purity.

Mass spectrometry (MS) complements HPLC by confirming molecular weight. A peptide like Epithalon (Ala-Glu-Asp-Gly) has an expected molecular weight of 390.35 Da—mass spec confirms whether the synthesized peptide matches within ±0.5 Da. MS detects gross synthesis errors (wrong amino acid entirely) and truncations but struggles with positional isomers where the sequence is correct but amino acids appear in the wrong order. HPLC catches positional errors because the retention time shifts even when molecular weight matches.

Purity percentages don't account for water content, counterions, or buffer salts—those appear separately on certificates of analysis as residual moisture and ash content. A peptide listed as 98% pure with 3% water and 1% acetate means 98% of the dry peptide mass is the target sequence. Lyophilized peptides naturally absorb atmospheric moisture during handling—typical water content ranges from 2–5% depending on storage conditions. This is why dosing calculations should reference net peptide content, not vial weight.

In our experience working with researchers using compounds like Tesamorelin and CJC-1295, the most common purity-related error is assuming the labeled purity applies to the entire vial contents. It doesn't—it applies to the peptide fraction after accounting for moisture and salts. A 10mg vial of 98% pure peptide with 4% water contains approximately 9.6mg of dry powder, of which 98% (9.41mg) is the target sequence. Dose calculations that ignore water content systematically overdose by 3–5%.

The Functional Differences Between 95%, 98%, and 99% Peptide Purity Levels

Peptide purity levels aren't just a quality marker—they predict experimental reproducibility and receptor pharmacology. The jump from 95% to 98% purity eliminates the majority of deletion peptides and truncated sequences that interfere with binding assays, cell culture studies, and dose-response curves. For peptides acting on high-affinity receptors—compounds like PT-141 or Kisspeptin-10—the difference between purity grades determines whether your data replicates or whether you're troubleshooting phantom variables for three months.

At 95% purity, the remaining 5% includes deletion peptides (sequences missing one or more amino acids at the N- or C-terminus), substitution analogs (wrong amino acid inserted during synthesis), and incomplete deprotection products where side-chain protecting groups weren't fully removed. These aren't inert—they occupy the same general hydrophobicity and molecular weight range as the target, meaning they co-elute during purification and remain in the final product. In receptor binding studies, deletion peptides can function as partial agonists or competitive antagonists depending on which residues are missing. A BPC-157 sample at 95% purity with 5% truncated sequences produces dose-response curves that don't plateau cleanly because the truncations compete for binding sites without full activation.

98% purity eliminates most deletion peptides through additional purification cycles—typically a second RP-HPLC pass with tighter gradient control. This is the minimum threshold for peer-reviewed publications involving receptor binding assays, EC50 determination, and dose-response pharmacology. Research using Thymalin or Selank at 98% purity produces reproducible results across labs because the impurity fraction is small enough that it doesn't statistically shift the observed effect.

99% purity represents pharmaceutical-grade synthesis with multiple purification passes and rigorous analytical validation. The final 1% impurity consists primarily of enantiomeric impurities (D-amino acids instead of L-amino acids), positional isomers, and trace reagent carryover. For most research applications, the functional difference between 98% and 99% is negligible—the remaining impurities don't interfere with mechanism because they lack receptor affinity. The exception is long-term stability studies and formulation development, where even trace impurities can seed aggregation or oxidation over months of storage.

Here's the honest answer: if you're running dose-response curves, binding assays, or publishing results, don't use peptides below 98% purity. The cost difference between 95% and 98% is 15–25%, but the experimental risk isn't worth it. We've seen researchers burn through three batches of cells trying to replicate a result before realizing the peptide purity was the variable. At Real Peptides, compounds like Ipamorelin and Hexarelin ship at 98%+ because that's the threshold where research stops being troubleshooting.

Peptide Purity Levels: Quality Grade Comparison

Not all purity percentages perform identically in research settings. This table outlines the synthesis characteristics, typical impurity profiles, and appropriate research applications for each purity grade.

Purity Grade	Synthesis Method	Typical Impurity Profile	Appropriate Research Use	Cost Relative to 98%	Bottom Line
95–96%	Standard solid-phase synthesis, single RP-HPLC purification	4–5% deletion peptides, truncated sequences, incomplete side-chain deprotection	Preliminary screening, non-binding studies, method development where mechanism isn't critical	70–80%	Acceptable for optimization work but not for dose-response or receptor studies—impurities interfere with binding assays
97–98%	Solid-phase synthesis with optimized coupling, dual RP-HPLC purification passes	2–3% deletion peptides, trace substitution analogs, residual protecting groups	Receptor binding assays, cell culture, dose-response studies, publishable research	Baseline (100%)	Minimum threshold for reproducible mechanistic research—this is the standard for peer-reviewed peptide pharmacology
99%+	Pharmaceutical-grade synthesis, multiple purification cycles, MS validation	<1% enantiomers, positional isomers, trace reagent carryover—no significant deletion peptides	Clinical-grade formulation, long-term stability studies, regulatory submissions	140–160%	Necessary for formulation development and GMP production but overkill for most laboratory research—98% delivers equivalent results in binding studies

The practical difference between 95% and 98% purity isn't linear—it's the elimination of specific impurity classes that interfere with receptor pharmacology. A peptide at 95% purity doesn't deliver 95% of the intended effect; it delivers unpredictable results because deletion peptides occupy receptors without activating them. For research-grade applications involving compounds like Sermorelin or CJC-1295, 98% is the reliability threshold.

What If: Peptide Purity Levels Scenarios

What If My Peptide's Certificate of Analysis Shows 96% Purity Instead of the Advertised 98%?

Contact the supplier immediately and request a replacement or refund—batch-to-batch variation should not drop below the advertised specification by more than 0.5%. Verify the COA lists batch number, synthesis date, and analytical method (RP-HPLC with gradient details). Legitimate suppliers like Real Peptides provide batch-specific documentation with HPLC chromatograms showing the target peak and impurity profile. If the purity drop is consistent across multiple batches, the supplier's synthesis or purification process has degraded—source from a provider with documented quality control like our full peptide collection where every batch ships with third-party verification.

What If I'm Using a 95% Pure Peptide and My Dose-Response Curve Won't Plateau?

The deletion peptides in the remaining 5% are likely competing for receptor binding without full activation, shifting your EC50 and preventing saturation. Switch to a 98% pure batch of the same peptide and re-run the assay—if the curve now plateaus cleanly, impurity interference was the variable. This is common with peptides like Ipamorelin or Hexarelin where truncated sequences missing the C-terminal residues bind growth hormone secretagogue receptors but fail to activate the Gq signaling cascade. You're not seeing bad technique—you're seeing pharmacological interference from synthesis by-products.

What If the HPLC Chromatogram on My COA Shows Multiple Peaks—Does That Mean My Peptide Is Contaminated?

Not necessarily—HPLC chromatograms always show multiple peaks because no synthesis is 100% pure. The target peptide appears as the dominant peak, with smaller peaks representing deletion sequences, salts, and residual solvents. Purity percentage is the area under the target peak divided by total peak area. Examine the chromatogram: if the target peak accounts for 98% of the total area and the remaining peaks are small (each <1%), the peptide meets research-grade standards. If you see a second large peak representing 5–10% of the total area, that's a deletion peptide—the batch doesn't meet spec and should be rejected. Real Peptides provides annotated chromatograms that label the target peak and identify major impurities so you're not interpreting raw HPLC output.

What If My Peptide Clumps or Doesn't Dissolve Fully After Reconstitution—Is That a Purity Issue?

Poor solubility usually indicates lyophilization technique or counterion selection, not purity. Peptides synthesized as trifluoroacetate (TFA) salts dissolve faster than acetate salts but are more hygroscopic and harder to dose accurately. If a peptide won't dissolve in bacteriostatic water at the expected concentration, try adjusting pH slightly with dilute acetic acid (lower pH for basic peptides) or ammonium hydroxide (raise pH for acidic peptides). If the peptide still clumps, aggregation may have occurred during storage due to temperature excursions above 8°C—aggregated peptides are functionally inactive even if HPLC purity was correct at synthesis. Request a replacement and verify cold chain integrity during shipping.

The Unvarnished Truth About Peptide Purity Levels

Let's be direct: most peptide suppliers advertise 98% purity but ship 95–96%, and researchers don't verify because they assume the COA matches the website claim. It doesn't. Batch-to-batch variation is real, and unless you're reading the HPLC chromatogram yourself, you're trusting marketing copy. We've reviewed COAs from competitors that list 98% purity in the summary but show a dominant HPLC peak at 94% when you calculate the area integration manually. The problem isn't deliberate fraud—it's rounding conventions and analytical method differences. A peptide measured at 97.4% on one HPLC system reads as 96.1% on another with different column chemistry and gradient timing.

The second uncomfortable truth: for most cell culture and binding assays, the difference between 96% and 98% purity doesn't matter if the impurities are random. The problem is when impurities aren't random—when they're deletion peptides missing the receptor-binding domain or truncated sequences that act as antagonists. A BPC-157 sample with 97% purity and 3% N-terminal deletions performs worse than a 96% pure sample with 4% random salts and solvents because the deletions interfere with mechanism. Purity percentage alone doesn't tell you what the impurities are.

Third-party verification is the only way to validate peptide purity levels, and most suppliers don't provide it. A certificate of analysis printed on company letterhead means nothing unless it includes batch number, synthesis date, HPLC chromatogram, and mass spectrometry data with the testing lab's name and contact information. At Real Peptides, compounds like Thymosin Alpha 1 and Epithalon ship with third-party COAs from accredited labs—not in-house testing reported by the same entity that synthesized the peptide. The conflict of interest is obvious. If your supplier won't provide independent verification, assume the purity is lower than advertised and dose accordingly.

Peptide purity levels aren't the most exciting part of experimental design, but they're the variable that determines whether your results replicate or whether you spend six months troubleshooting a synthesis problem you didn't cause. Choose your supplier based on documented purity and third-party verification—not price per milligram. At Real Peptides, we prove purity for every batch because research-grade means research-reproducible. Explore high-purity research peptides across our complete collection and see the difference third-party verification makes when results matter.

If the chromatogram doesn't match the claim, don't use the peptide. It's that simple. Purity specifications exist because receptor pharmacology is unforgiving—truncated sequences don't produce truncated effects, they produce unpredictable interference. The 2–3% purity difference between commodity peptides and research-grade synthesis is the difference between publishable data and noise.

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Peptide purity is measured using reverse-phase high-performance liquid chromatography (RP-HPLC), which separates molecules by hydrophobicity and size. The purity percentage represents the proportion of correctly sequenced, full-length target peptide relative to the total peptide content, calculated by dividing the area under the target peak by the total area of all detected peaks on the chromatogram. A 98% pure peptide means 98% of the dry peptide mass (excluding water and salts) is the intended amino acid sequence, with the remaining 2% consisting of deletion sequences, truncated chains, and synthesis by-products. Mass spectrometry complements HPLC by confirming molecular weight within ±0.5 Da, catching gross synthesis errors that HPLC retention time alone might miss.

For receptor binding assays, dose-response studies, and any research intended for publication, 98% purity is the minimum reliable threshold. The 3–5% impurity fraction in 95% pure peptides typically consists of deletion sequences and truncated analogs that can bind to the same receptors as the target peptide but without full activation—functioning as competitive antagonists that shift EC50 values and prevent dose-response curves from plateating cleanly. This interference makes data irreproducible across experiments. The cost difference between 95% and 98% purity is 15–25%, but the experimental risk of using lower-purity peptides in mechanistic research consistently outweighs the savings when results don’t replicate.

The remaining 2% in a 98% pure peptide consists primarily of deletion peptides (sequences missing one or more amino acids at the N- or C-terminus), truncated chains from incomplete synthesis cycles, substitution analogs where the wrong amino acid was inserted during coupling, and incomplete deprotection products where side-chain protecting groups weren’t fully removed. At 98% purity, most deletion peptides have been eliminated through additional RP-HPLC purification passes, leaving trace amounts of enantiomeric impurities (D-amino acids instead of L-amino acids), positional isomers, and residual synthesis reagents. These remaining impurities at the 2% level generally lack significant receptor affinity and don’t interfere with pharmacological mechanism, which is why 98% is the research-grade standard for reproducible binding studies.

Request a batch-specific certificate of analysis (COA) that includes the batch number, synthesis date, HPLC chromatogram with labeled target peak, mass spectrometry data, and the name and contact information of the third-party testing laboratory. The HPLC chromatogram should show the target peptide as the dominant peak with area integration percentages listed—calculate the purity yourself by dividing the target peak area by total peak area to verify it matches the advertised specification. Legitimate research-grade suppliers provide COAs from accredited independent labs, not in-house testing reported by the same entity that synthesized the peptide. If a supplier cannot provide third-party verification with batch-specific analytical data, assume the purity is lower than advertised and source from a provider with documented quality control like Real Peptides.

Peptide purity primarily affects immediate experimental reproducibility rather than storage stability—the impurities present at synthesis (deletion peptides, truncations) remain constant during storage unless degradation occurs. However, trace impurities can seed aggregation or oxidation during long-term storage, particularly in reconstituted solutions where water accelerates chemical degradation. Lyophilized peptides stored at −20°C maintain purity for 12–24 months regardless of whether they’re 95% or 98% pure at synthesis. Once reconstituted with bacteriostatic water, peptides should be stored at 2–8°C and used within 28 days—purity will decline due to oxidation, aggregation, and hydrolysis, with higher-purity starting material degrading at roughly the same rate as lower-purity peptides once in solution.

HPLC purity measures the percentage of correctly sequenced target peptide relative to total peptide content, excluding water, salts, and counterions. Peptide content by weight measures the actual mass of all peptide material (target plus impurities) relative to total vial weight, including water and salts. A vial labeled as 10mg of 98% pure peptide with 4% water and 1% acetate counterion contains approximately 9.5mg of dry peptide, of which 98% (9.31mg) is the target sequence. Dosing calculations that ignore water content and assume the entire 10mg is active peptide systematically overdose by 3–7%. Certificates of analysis list both HPLC purity and peptide content—multiply them to determine net active peptide mass per vial.

Price differences reflect synthesis difficulty, sequence length, amino acid rarity, and purification complexity beyond the final purity percentage. Peptides with multiple disulfide bonds like Thymosin Alpha 1 require additional oxidation and folding steps that increase synthesis time and reduce yield. Long sequences (>20 amino acids) accumulate deletion errors at each coupling step, requiring multiple purification passes to reach 98% purity. Peptides containing non-standard amino acids—D-amino acids, methylated residues, or beta-amino acids—require custom synthesis protocols and specialized protecting groups that cost 3–5× standard amino acids. Additionally, peptides with hydrophobic sequences aggregate during purification, reducing recovery yield and increasing cost per milligram of final product. A 98% pure 15-amino acid peptide with standard residues costs significantly less than a 98% pure 30-amino acid sequence with two disulfide bonds, even though both meet the same purity specification.

Mass spectrometry confirms molecular weight and detects gross synthesis errors (wrong amino acid entirely, missing residues) but cannot quantify purity because it doesn’t separate molecular species before measurement. MS detects whether the target molecular weight is present but doesn’t reveal what percentage of the sample is the target versus impurities. HPLC separates peptides by retention time before detection, allowing quantification of each component—the chromatogram shows exactly how much target peptide versus deletion sequences are present. Positional isomers (correct amino acids in wrong order) have identical molecular weight but different HPLC retention times, meaning MS alone cannot detect this critical synthesis error. Research-grade peptide verification requires both HPLC for purity quantification and MS for molecular weight confirmation—one method without the other provides incomplete validation.

First, verify the peptide purity level and calculate net peptide content accounting for water and counterions—a 5mg dose of 95% pure peptide with 5% water delivers approximately 4.5mg of active compound, not 5mg. Request the certificate of analysis and examine the HPLC chromatogram for large impurity peaks that indicate significant deletion peptide content. If the peptide purity is confirmed at 98%+ and net content calculations are correct, check storage conditions—temperature excursions above 8°C cause irreversible denaturation that neither appearance nor home potency testing can detect. Compare synthesis methods if the published study used a different supplier—acetate versus TFA salt forms affect solubility and effective concentration in buffer. If none of these variables explain the discrepancy, source a reference standard from the original study’s supplier or switch to a research-grade provider with third-party verification like Real Peptides to eliminate peptide quality as the experimental variable.

Yes—peptides acting on high-affinity receptors with nanomolar or sub-nanomolar binding constants are most sensitive to purity because even small amounts of deletion peptides can competitively inhibit binding without activating the receptor. Growth hormone secretagogues like Ipamorelin and Hexarelin, melanocortin receptor agonists like PT-141, and receptor-selective peptides like Kisspeptin-10 require 98%+ purity because truncated sequences missing the binding domain or C-terminal residues occupy receptors as partial agonists or antagonists. Conversely, peptides with lower receptor affinity or those acting through bulk mechanisms (antioxidants, cell-penetrating sequences) tolerate 95–96% purity with less functional impact. Any peptide used in dose-response studies, EC50 determination, or receptor pharmacology assays requires 98% minimum purity regardless of sequence—the experimental design demands reproducibility that lower purity grades cannot reliably deliver.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA